Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II GMZ2 malaria vaccine study in children
PACTR2010060002033537Phase 2Completed
- Sponsor
- Statens Serum Institut
- Start
- Jul 2010
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 4
01
Overview
Phase 2 trial of GMZ2 and rabies virus inactivated antigen, B in malaria (2 arms), sponsored by Statens Serum Institut. Primary endpoint: Efficacy. Started Jul 2010; status: completed.
02
Drugs
GMZ2rabies virus inactivated antigen, B
03
Conditions
malaria
Beyond the preview
Go deeper on PACTR2010060002033537.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR2010060002033537.